Abstract
Stages III and IV lymphosarcoma (LS) and reticulosarcoma (RS) are disseminated diseases that are typical indications for chemotherapy. Utilizing the drugs vincristine, cyclophosphamide, prednisone (12), adriamycin (6), bleomycin (4), nitrosoureas (5), VM 26 (20), and/or a few others (see [7] and [18]) and combinations of these drugs (8, 9, 10, 21, 22, 23, 24), chemotherapy has been shown to be able to induce a high rate of remission and to significantly but variably prolong survival due to several factors, the major factor being histologic classifications. One group [1] applied Lennert’s classification [11]. Most others used the classic Rappaport classification [25], including in the so-called “histiocytic” type several different types, some of which may have good prognosis, e.g., diffuse large cell prolymphocytic (centrofollicular) LS, some of which may have very severe prognosis, e.g., immunoblastic LS [15], and a few of which may have intermediate prognosis, e.g., RS, as discussed in this paper. The present work assesses the value of the WHO categorization [19] in which 1) tumors of the lymphocytic series are called LS and those of the fixed, so-called mononuclear phagocytes [32] (e.g., reticular cells, dendritic cells), which are not in fact macrophages [see 29, 30, 31], are called RS and 2) types of LS are distinguished according to the cell differentiation stages. Among the common varieties, the prolymphocytic (centrofollicular) nodular or diffuse type, the lymphoblastic type, and the immunoblastic type are recognized.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bartells, H., Brener, K., Brittinger, G., Burger, A., Druhmke, E., Gunzer, U., Konig, E., Stacher, A., Theml, H., Waldner, R.: Clinical significance of the Kiehl classification of the Non- Hodgkin’s lymphomas. Abstract S-19–5, p. 60. In: Abstracts of the 16th International Congress of Haematol., Kyoto, 1976
Belpomme, D., Lelarge, N., Mathé, G., Davies, A. J. S.: Etiological clinical and prognostic significance of the T-B immunological classification of primary acute lymphoid leukemias and non- Hodgkin’s lymphomas, pp. 33–45. In: “Immunological Diagnosis of Leukemias and Lymphomas” (Thierfelder, S., Rodt, H., Thiel, E. eds.) Heidelberg, New York: Springer, 1977
Belpomme, D., Caillou, B., Lelarge, N., Botto, I., Gerard-Marchant, A., Rappaport, H., Davies, A. J. S., Mathé, G.: Prognostic value and clinical significance of the T-B-“null” immunological classification of non-Hodgkin’s lymphomas: its correlation with other classifications. In: “Lymphoid Neoplasias II” (RRCR) (MATHÉ, G., Seligmann, M., Tubiana, M. eds.), pp. 28–40. Berlin- Heidelberg-New York: Springer, 1978
Blum, R. H., Carter, S. K., Agre, K.: A clinical review of bleomycin, an antineoplastic agent. Cancer, 31, 309 (1973)
Carter, S. K.: An overview of the status of the nitrosoureas in other tumours. Cancer Chemother. Rep., Part 3, 4, 35 (1973)
Carter, S. K., DI Marco, A., Ghione, M., Krakoff, I. H., MATHÉ, G. (eds.): Adriamycin. Berlin-Heidelberg-New York: Springer, 1972
Clarysse, A., Kenis, Y., Mathé, G.: Cancer chemotherapy (its role in the treatment strategy of hematologic malignancies and solid tumors). In: RRCR, Berlin-Heidelberg-New York: Springer, 1976, Vol. 53
De Vita, V. T., Canellos, G. P., Chabner, B. A., Schein, P., Hubbard, S. P., Young, R. C.: Advanced histiocytic lymphoma, a potentially curable disease: Results with combination chemotherapy. Lancet, 1, 248–250 (1975)
Garret, T. J., Gee, T. S., Dowling, M. D., Lee, B. J., Middleman, M. P., Clarkson, B. D., Young, C. W.: Cyclophosphamide L2 Protocol: A combination chemotherapeutic regimen for advanced non- Hodgkin’s lymphomas, Cancer Treat. Rep., 61, 7–16 (1977)
Gorin, N. C., David, R., Stachowiak, J., Najman, A., Duhamel, G.: Combination of cyclophosphamide, vincristine and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with Non-Hodgkin ’s lymphomas. Med. Pediatr. Oncol., 3, 41–51 (1977)
Lennert, K., Mohri, N., Stein, H., Kaiserling, E.: The histopathology of malignant lymphoma. Brit. J. Haematol., 31, Suppl. 193 (1975)
Livingston, R. B., Carter, S. K.: Single Agents in Cancer Chemotherapy. New York: Plenum Press 1970
Mathé, G.: Cancer active immunotherapy, immunoprophylaxis and immunorestoration. An introduction. In: RRCR, Berlin-Heidelberg-New York: Springer, 1976, Vol. 55
Mathé, G., Belpomme, D., Dantchev, D.: Les hématosarcomes non-hodgkiniens (classification du Centre de Référence de l’O.M.S.) Ann. Anat. Pathol., 21, 285–300 (1976)
Mathé, G., Belpomme, D., Dantchev, D., Khalil, A., Afifi, A. M., Taleb, N., Pouillart, P., SCHWARZENBERG, Hayat, M., De Vassal, F., Jasmin, C., Missett, J. L., Musset, M.: Immunoblastic lymphosarcoma, a cytological and clinical entity? Biomedicine, 22, 473–488 (1975)
Mathé, G., Belpomme, D., Dantchev, D., Pouillart, P.: Progress in the classification of lymphoid and/or monocytoid leukemias and or lympho- and reticulosarcomas. Biomedicine, 22, 177–185 (1975)
MATHÉ, G., Belpomme, D., Misset, J. L.: Integration of modern data in W.H.O. categorisation of lymphosarcomas. Its value for prognosis prediction and therapeutic adaptation to prognosis. Biomedicine, 1977. (In press)
Mathé, G. and Kenis, Y.: La Chimiothérapie des Cancers (Leucémies, Hématosarcomes et Tumeurs Solides). 3ème ed., Paris. Expansion Scientifique Française, 1975, 1 vol.
Mathé, G., Rappaport, H., O’Conor, G. T., Torloni, H.: Histological and cytological typing of neoplastic diseases of haematopoietic and lymphoid tissues. Geneva: W.H.O., 1976
Mathé, G., Schwarzenberg, L., Pouillart, P., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., De Vassal, F.: Two epipodophyllotoxin derivatives VM26 and VP 16213, in the treatment of leukemias, hematosarcomas and lymphomas. Cancer, 34, 985–992 (1974)
Misset, J. L., Pouillart, P., Amiel, J. L., Schwarzenberg, L., Hayat, M., De Vassal, F., Misset, M., Belpomme, D., Jasmin, C., Albahary, C., Depierre, R., Mathé, G.: Combinaisond’adrimaycine, de VM26, de cyclophosphamide et de prednisone (AVmCP) pour la chimiothérapie des lymphoréti- culosarcomes disséminés (Stades ou formes topographiques III et IV). Nouv. Presse. Méd., 4, 3117–3120(1975)
Monfardini, S., Tancini, G., De Lena, M., Villa, E., Valagussa, P., Bonadonna, G.: Cyclophosphamide, vincristine, and prednisone (C VP) versus adriamycin, bleomycine, and prednisone (ABP) in stage IV non-Hodgkin’s lymphomas. Med. Pediatr. Oncol., 3, 67–74 (1977)
O’Connell, M. J., Silverstein, M. N., Kiely, J. M., White, W. L.: Pilot study of two adriamycin- based regimens in patients with advanced malignant lymphomas. Cancer Treat. Rep., 61, 65–68 (1977)
Portlock, C. S., Rosenberg, S. A.: Combination chemotherapy with cyclophosphamide, vincristine and prednisone in advanced non-Hodgkin’s lymphomas. Cancer, 37,1275–1282 (1976)
Rappaport, H.: Tumours of the hematopoietic system. Washington D. C., Armed Forces Institutes of Pathology, 1966, pp. 91–206
Skipper, H. E., Schabel, F. M., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother. Rep., 35, 1–111 (1964)
Skipper, H. E., Schabel, F. M., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother. Rep. 45, 5–28 (1965)
Skipper, H. E., Schabel, F. M., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukaemic cells. Cancer Chemother. Rep., 51, 125–165 (1967)
Steinman, R. M., Adams, J. C., Cohn, Z. A.: Identification of novel cell type in peripheral lymphoid organs of mice. III. Identification and distribution in mouse spleen. J. Exp. Med., 141, 808, 1975
Steinman, R. M., Cohn, Z. A.: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantification, tissue distribution. J. Exp. Med., 137, 1142 (1973)
Steinman. R. M., Lustig, D. S., Cohn, Z. A.: Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vivo. J. Exp. Med., 139, 1431 (1974)
Van Furth, R., Cohn, Z. A., Hirsch, J. G., Humphrey, J. H., Spector, W. G., Langevoort, H. L.: The mononuclear phagocyte system: a new classification of macrophages, monocytes and their precursor cells. Bull. W.H.O., 48, 845–852 (1972)z
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Misset, J.L. et al. (1978). Preliminary Results of Chemoradiotherapy Followed (or Not) by Active Immunotherapy of Stage III and IV Lymphosarcoma and Reticulosarcoma: Correlation of the Results with WHO Categorization. In: Mathé, G., Seligmann, M., Tubiana, M. (eds) Lymphoid Neoplasias II. Recent Results in Cancer Research, vol 65. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81249-1_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-81249-1_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81251-4
Online ISBN: 978-3-642-81249-1
eBook Packages: Springer Book Archive